临床实践进展:COVID-19大流行期间炎症性肠病的管理
本文综述了炎症性肠病(IBD)患者感染SARS-CoV-2的风险、相关结局及最新疫苗指南。已有证据提示,常用IBD药物中糖皮质激素(而非生物制剂)与COVID-19不良结局相关;抗TNF治疗者疫苗体液应答减弱且抗体衰减更快,但突破性感染和住院率在所有接种疫苗患者中均保持低水平。国际指南推荐接受免疫抑制治疗的IBD患者在任何治疗周期点接种三剂SARS-CoV-2疫苗基础剂量,并尽快接种加强针。
要点
- 糖皮质激素(而非生物制剂)与IBD患者COVID-19不良结局相关。
- 抗TNF治疗者疫苗体液应答减弱、抗体衰减更快,但突破性感染和住院率低。
- 国际指南推荐免疫抑制治疗的IBD患者接种三剂基础疫苗并尽快加强。
核心结论
- 常用IBD药物中糖皮质激素(而非生物制剂)与COVID-19不良结局相关。
- 抗TNF治疗者疫苗体液应答减弱且抗体衰减更快,但接种疫苗者突破性感染和住院率保持低水平。
- 国际指南推荐接受免疫抑制治疗的IBD患者接种三剂SARS-CoV-2疫苗基础剂量并尽快接种加强针。
- 未来研究应关注生物制剂治疗者抗体衰减速率、需额外疫苗剂量的人群、COVID-19对IBD病程的长期风险及长期COVID-19风险。
研究设计与样本
- 综述,总结IBD患者COVID-19风险、相关结局及SARS-CoV-2疫苗最新指南。
主要发现
- 常用IBD药物中糖皮质激素(而非生物制剂)与COVID-19不良结局相关。
- 未观察到新发或延迟IBD诊断风险增加,但内镜操作总体减少导致大流行期间内镜检出癌症数量上升。
- 抗TNF治疗者较非抗TNF治疗者疫苗体液应答减弱且抗体衰减更快。
- 所有接种疫苗患者无论IBD治疗如何,突破性感染和住院率均保持低水平。
关键数值与推荐
- 国际指南推荐:接受免疫抑制治疗的IBD患者应在治疗周期任意时间点接种三剂SARS-CoV-2疫苗基础剂量,并尽快接种加强针。
临床怎么用
- 国际指南推荐接受免疫抑制治疗的IBD患者接种三剂SARS-CoV-2疫苗基础剂量并尽快加强。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has raised considerable concerns that patients with inflammatory bowel disease (IBD), particularly those treated with immunosuppressive therapies, may have an increased risk of SARS-CoV-2 acquisition, develop worse outcomes following COVID-19, and have suboptimal vaccine response compared with the general population. In this review, we summarise data on the risk of COVID-19 and associated outcomes, and latest guidance on SARS-CoV-2 vaccines in patients with IBD. Emerging evidence suggests that commonly used medications for IBD, such as corticosteroids but not biologicals, were associated with adverse outcomes to COVID-19. There has been no increased risk of de novo, or delayed, IBD diagnoses, however, an overall decrease in endoscopy procedures has led to a rise in the number of missed endoscopic-detected cancers during the pandemic. The impact of IBD medication on vaccine response has been a research priority recently. Data suggest that patients with IBD treated with antitumour necrosis factor (TNF) medications had attenuated humoral responses to SARS-CoV-2 vaccines, and more rapid antibody decay, compared with non-anti-TNF-treated patients. Reassuringly, rates of breakthrough infections and hospitalisations in all patients who received vaccines, irrespective of IBD treatment, remained low. International guidelines recommend that all patients with IBD treated with immunosuppressive therapies should receive, at any point during their treatment cycle, three primary doses of SARS-CoV-2 vaccines with a further booster dose as soon as possible. Future research should focus on our understanding of the rate of antibody decay in biological-treated patients, which patients require additional doses of SARS-CoV-2 vaccine, the long-term risks of COVID-19 on IBD disease course and activity, and the potential risk of long COVID-19 in patients with IBD.
引用
- Lin S, Lau LH, Chanchlani N, et al. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2022. PMID: 35477864. doi:10.1136/gutjnl-2021-326784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。